Alnylam Pharmaceuticals, Inc (ALNY)

82.07
2.82 3.32
NASDAQ
Prev Close 84.89
Open 85.06
Day Low/High 79.79 / 86.23
52 Wk Low/High 60.27 / 153.99
Volume 1.36M
Exchange NASDAQ
Shares Outstanding 106.44B
Market Cap 9.43B
Div & Yield N.A. (N.A)
Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Deutsche Bank 41 st Annual Health Care Conference on...

Alnylam To Webcast Conference Call Discussing First Quarter 2016 Financial Results

Alnylam To Webcast Conference Call Discussing First Quarter 2016 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2016 on Monday, May 2, 2016, after the...

Alnylam Reports Complete 18-Month Data From Ongoing Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)

Alnylam Reports Complete 18-Month Data From Ongoing Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today complete 18-month data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi...

Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today

Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam To Webcast Presentation At 15th Annual Needham Healthcare Conference

Alnylam To Webcast Presentation At 15th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 15 th Annual Needham Healthcare Conference on Wednesday,...

Somber Sentiment Makes Me Wonder

I still see an April correction and then a rally, but sentiment is a worry.

Alnylam Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase 1 Study

Alnylam Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase 1 Study

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has initiated dosing of hemophilia patients with inhibitors in Part D of an ongoing Phase 1 clinical trial...

Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More

Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More

Here are Friday's top research calls, including upgrades for Chevron, Hertz and Kohl's, and a downgrade for Blackstone.

3 Stocks Pulling The Drugs Industry Downward

3 Stocks Pulling The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-GO1, a subcutaneously administered investigational RNAi...

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Cowen and Company 36 th Annual Healthcare Conference on...

Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today

Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2015, and highlighted recent progress on its...

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2015 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2015 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2015 on Thursday, February...

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the 18 th Annual BIO CEO & Investor Conference on Tuesday,...

Alnylam Completes Enrollment In APOLLO Phase 3 Study With Patisiran, An Investigational RNAi Therapeutic For Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Completes Enrollment In APOLLO Phase 3 Study With Patisiran, An Investigational RNAi Therapeutic For Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has completed enrollment - with well over 200 patients accrued - in its APOLLO Phase 3 study with patisiran,...

Weak On High Volume: Alnylam Pharmaceuticals (ALNY)

Weak On High Volume: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Pharmaceuticals (ALNY): Today's Weak On High Volume Stock

Alnylam Pharmaceuticals (ALNY): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Outlines 2016 Goals For RNAi Therapeutics Pipeline

Alnylam Outlines 2016 Goals For RNAi Therapeutics Pipeline

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today its pipeline goals for 2016 across its Genetic Medicine, Cardio-Metabolic Disease, and Hepatic Infectious Disease...

Alnylam To Webcast Presentation At 34th Annual J.P. Morgan Healthcare Conference

Alnylam To Webcast Presentation At 34th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 34 th Annual J.

Alnylam To Webcast Presentation At Goldman Sachs "Healthcare CEOs Unscripted: A View From The Top" Conference

Alnylam To Webcast Presentation At Goldman Sachs "Healthcare CEOs Unscripted: A View From The Top" Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs "Healthcare CEOs Unscripted: A View from the...

Sell These 6 Biotech Stocks Now Before It's Too Late

Sell These 6 Biotech Stocks Now Before It's Too Late

Biotech stocks are set to outperform in 2015, but here are six stocks that investors should steer clear of in 2016.

Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has filed a Clinical Trial Application (CTA) with the U.

Alnylam Announces Updates To Company's Board Of Directors Supportive Of Transition Towards Commercial Stage

Alnylam Announces Updates To Company's Board Of Directors Supportive Of Transition Towards Commercial Stage

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Michael Bonney, current Board member and former chief executive of Cubist Pharmaceuticals, has been appointed as...

Alnylam Initiates Dosing In PNH Patients In Phase 1/2 Clinical Trial For ALN-CC5

Alnylam Initiates Dosing In PNH Patients In Phase 1/2 Clinical Trial For ALN-CC5

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it initiated the final phase (Part C) of its Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered...

Alnylam Pharmaceuticals To Present Path To "Alnylam 2020" At R&D Day

Alnylam Pharmaceuticals To Present Path To "Alnylam 2020" At R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today at a presentation in New York City will discuss pipeline progress across its three strategic therapeutic areas (STArs)...

Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)

Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Alnylam Reports Positive Phase 1 Study Results For Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) In Patients With Hemophilia A And B

Alnylam Reports Positive Phase 1 Study Results For Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) In Patients With Hemophilia A And B

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today positive results from its ongoing Phase 1 clinical study with fitusiran (fi-TOO-si-ran), the recommended...

Alnylam Reports That ALN-CC5 Achieves Up To 99 Percent Knockdown Of Serum C5 And Up To 98 Percent Inhibition Of Serum Hemolytic Activity With Durability Supportive Of Once Monthly And Possibly Once Quarterly Subcutaneous Dose Regimen

Alnylam Reports That ALN-CC5 Achieves Up To 99 Percent Knockdown Of Serum C5 And Up To 98 Percent Inhibition Of Serum Hemolytic Activity With Durability Supportive Of Once Monthly And Possibly Once Quarterly Subcutaneous Dose Regimen

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today positive interim results from its ongoing Phase 1/2 clinical study with ALN-CC5, an investigational RNAi therapeutic...

3 Drugs Stocks Moving The Industry Upward

3 Drugs Stocks Moving The Industry Upward

TheStreet highlights 3 stocks pushing the drugs industry higher today.

TheStreet Quant Rating: D (Sell)